Myogen Getting Lean and Mean

Myogen, Inc. (Nasdaq: MYOG) has sold its wholly-owned European subsidiary Myogen GmbH for $6.1 million to Wulfing Holding GmbH. The deal centers around a sublicense for rights to Perfan® I.V. (intravenous enoximone) in markets outside North America, from which the former parent will continue to receive a royalty on future net sales.

Shedding this particular asset should enable a laser sharp focus upon Myogen’s development-stage products, ambrisentan and darusentan.

J. William Freytag, President and Chief Executive Officer, will present a corporate overview at the NASDAQ US Small Cap Conference to be held in London, 7 February.